Iqvia Holdings, Inc. · NYSE:IQV
Iqvia — IQVIA Life Sciences Innovation Forum (September 2022)
13 slides from Iqvia's conference presentation, Sep 14, 2022
Slide 1: IQVIA Life Sciences Innovation Forum: Maximizing the Value of Medicines to Patients
IQVIA Life Sciences Innovation Forum S e t - u p S l i d e s : M a x i m i z i n g t h e Va l u e o f Medicines to Patients September 14, 2022 Copyright © 2021 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.
Slide 2: Ensuring the right medicines are delivered to the right patients at the right time
Ensuring the right medicines are delivered to the right patients at the right time has been a long-time priority for health systems This set of 6 levers were the focus of research published back in 2012 Use expensive therapies through predictive diagnostics Use low-cost generics where available Incr
Slide 3: Since 2012, ~550 New Active Substances have launched and annual medicine spending has reached $1.4Tn
Since 2012, ~550 New Active Substances (NAS) have launched and annual medicine spending has reached $1.4Tn A total of 329 novel active substances have launched Global medicine market has been growing and is estimated globally in the past 5 years, bringing the 20-year total to 883 to be ~$1.4Tn in 20
Slide 4: Increasing share of specialty and orphan drugs among new active substances
Out of the New Active Substances launched, there has been an increasing share of specialty and orphan drugs U.S. novel active substance (NASs) by product attributes, 2012-2021 Specialty Orphan 100% 90% 80% 69% 70% 57% 60% 56% 50% 40% 27% 30% 20% 10% 0% 2012 2013 2014 2015 2016 2017 2018 2019 2020 20
Slide 5: Time from global launch to reimbursement can be 6 to 44 months
However, patient access to these medicines can see delays as the time from global launch to reimbursement can be 6 to 44 months Time from global launch to country reimbursement (months) 140 120 100 80 60 40 41 44 43 38 31 33 31 32 27 26 27 20 20 20 22 19 17 16 17 14 14 16 9 9 9 10 6 0 Minimum Median
Slide 6: >400 drugs have launched in the US with biomarkers
>400 drugs have launched in the US with biomarkers; however, several barriers limit the optimal use of these biomarkers >400 Drug with Pharmacogenomic Biomarkers in Drug Labeling (FDA) 5 Source: FDA; Optimizing Oncology Care Through Biosimilar Adoption, IQVIA Institute, 2020
Slide 7: Diagnostic delays exist in several conditions and can impact the delivery of appropriate care
Diagnostic delays exist in several conditions and can impact the delivery of appropriate care Diagnostic Delay in Pediatric Inflammatory Bowel Disease, Diagnostic Delay in COPD (In days) Crohn’s Disease and Ulcerative Colitis (In Months) PIBD CD UC 25 4 – 24 430 20 2 - 18 300 15 2 – 10.4 210 10 100
Slide 8: Patient adherence remains a challenge with <50% persisting after 1 year
Patient adherence remains a challenge with <50% of patients persisting on treatment after 1 year for several conditions Percentage of patients remaining on therapy 7 Source: 12-month persistence, IQVIA LAAD Claims Data
Slide 9: 47 million unnecessary antibiotic prescriptions are written in the U.S. each year
47 million unnecessary antibiotic prescriptions are written in the U.S. each year, contributing to antibiotic resistance According to the CDC, 47 million unnecessary antibiotic prescriptions are written in the United States each year Mapping of Antibiotic prescriptions per 1000 people shows variabil
Slide 10: Savings from biosimilar and generic use are increasing
Savings from biosimilar and generic use are increasing, however, biosimilar use remains variable and further savings are possible Annual Savings from Generics in USA ($Bn) 400 371 350 338 314 300 286 263 240 Annual Savings ($Bn) 250 219 193 200 200 166 150 100 50 2012 2013 2014 2015 2016 2017 2018 2
Slide 11: Home care and associated technologies are growing in importance
Home care and associated technologies are growing in importance & will play a crucial role in management of medicines 10 Source: Digital Health Trends, IQVIA Institute, 2021
Slide 12: Achieving equity in medicine use is critical
Achieving equity in medicine use is critical as per capita use in developed countries is nearly double of pharmerging use Historical and projected per capita use of medicine by segment, 2011–2026 Forecast 900 5-Year 5-Year 5-Year 800 CAGRs CAGRs CAGRs 0.9% 0.6% 0.3% 700 DDD per capita 600 500 3.0% 1
Slide 13: Equity of medicine use is also impacted by socioeconomic and race/ethnicity
Equity of medicine use is also impacted by socioeconomic and race/ethnicity resulting in varying healthcare outcomes Lower use of monoclonal antibody treatment among Black, Black, Hispanic, and AIAN people fare worse than White Asian, and Other race and Hispanic patients with positive SARS- people a
IQVIA Holdings — IQVIA Life Sciences Innovation Forum (September 2022) on 6ix